Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2791 to 2805 of 9098 results

  1. Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

    Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

  2. Bile acid malabsorption: colesevelam (ESUOM22)

    Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

  3. Postural hypotension in adults: fludrocortisone (ESUOM20)

    Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

  4. Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)

    Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making

  5. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  6. Premature ejaculation: dapoxetine (ESNM40)

    Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making

  7. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  8. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

  9. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  10. Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

    Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

  11. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

    Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

  12. Cancer: breast cancer mortality rate (IND4)

    This indicator covers breast cancer mortality rates (female). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG04

  13. Cancer: breast screening (53 to 70 years) (IND65)

    This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84

  14. Board committees

    Our board has 2 sub-committees: the audit and risk assurance committee and the remuneration committee.

  15. Screening: cervical screening (50 to 64 years) (IND177)

    This indicator covers the proportion of patients eligible for cervical screening and aged 50 to 64 years at end of period reported whose notes record that an adequate cervical screening test has been performed in the previous 5.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM155